Repare Therepautics will provide updated clinical data for PKMYT1 inhibitor lunresertib + ATR inhibitor camonsertib in Q4, possibly at the Triple Meeting October 23-25 in Barcelona, though management has not committed to a specific venue, LifeSci Capital analyst Charles Zhu tells investors. The firm, which made no change to its Outperform rating and $8 price target, sees a potential +400%/-50% upside/downside in shares coming out of the event.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare Therapeutics Advances Oncology Trials and Preps for 2025
- Repare Therapeutics files $350M mixed securities shelf
- Repare Therapeutics expects cash to fund operations into mid-2026
- Repare Therapeutics reports Q2 EPS (82c), consensus (87c)
- Repare Therapeutics management to meet virtually with Piper Sandler